Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 28, 2020 23:50 ET | Source: Immunomedics

Immunomedics Announces Pricing of Public Offering of Common Stock

MORRIS PLAINS, N.J., April 28, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
April 27, 2020 16:01 ET | Source: Immunomedics

Immunomedics Announces Proposed Public Offering Of Common Stock

MORRIS PLAINS, N.J., April 27, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
April 23, 2020 08:00 ET | Source: Immunomedics, Inc.

Multimedia Update: FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...
April 22, 2020 11:47 ET | Source: Immunomedics

FDA Grants Accelerated Approval for Immunomedics’ Trodelvy in Previously-Treated Metastatic Triple-Negative Breast Cancer

First FDA-approved antibody-drug conjugate that targets the Trop-2 antigen Trodelvy is the first antibody-drug conjugate approved by FDA specifically for the treatment of relapsed or refractory...
April 07, 2020 09:28 ET | Source: Immunomedics

CORRECTION - FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR LOCALLY-ADVANCED OR METASTATIC UROTHELIAL CANCER

MORRIS PLAINS, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- In a release issued earlier today by Immunomedics, Inc. (Nasdaq:IMMU), the headline was inaccurate. The cancer is accurately described as...
April 07, 2020 08:00 ET | Source: Immunomedics

FDA GRANTS FAST TRACK DESIGNATION TO SACITUZUMAB GOVITECAN FOR NEOADJUVANT/ADJUVANT METASTATIC UROTHELIAL CANCER

MORRIS PLAINS, N.J., April 07, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
April 06, 2020 08:00 ET | Source: Immunomedics

IMMUNOMEDICS ANNOUNCES ASCENT STUDY TO BE STOPPED FOR COMPELLING EFFICACY

Decision based on recommendation from DSMC following study data review Sacituzumab govitecan has the potential to be the first FDA-approved antibody-drug conjugate for the treatment of metastatic...
April 06, 2020 07:50 ET | Source: Immunomedics

IMMUNOMEDICS ANNOUNCES EXECUTIVE LEADERSHIP CHANGES AND THE APPOINTMENT OF HAROUT SEMERJIAN AS PRESIDENT AND CHIEF EXECUTIVE OFFICER

MORRIS PLAINS, N.J., April 06, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
April 03, 2020 17:00 ET | Source: Immunomedics

IMMUNOMEDICS TO HOST CONFERENCE CALL AND WEBCAST ON APRIL 6, 2020 TO PROVIDE CLINICAL AND CORPORATE UPDATE

MORRIS PLAINS, N.J., April 03, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...
March 25, 2020 08:00 ET | Source: Immunomedics

IMMUNOMEDICS PROVIDES COVID-19 BUSINESS CONTINUITY UPDATE, AFFIRMS 2020 STRATEGIC PRIORITIES, AND SHARES R&D AND REGULATORY UPDATE

MORRIS PLAINS, N.J., March 25, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right